● TIER 1 — FDA-approved / recognizedGRADE AMetabolic (other)
Octreotide / Lanreotide
Somatostatin analogs. Research verification: Yes (TGA pending). 2 human study record(s) in the FitClinicMD studies database.
FDA status
Approved: Sandostatin/LAR, Mycapssa; Somatuline Depot.
Compounding (503A/503B)
Approved.
DEA
Not controlled.
WADA (sport)
Not listed on 2026 Prohibited List (no matching section found)
Mechanism
SSTR2/5 agonists.
Human evidence · 2
Trial Lanreotide in metastatic enteropancreatic neuroendocrine tumors.
PROMID, n=85 midgut NETs. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group.
Reference only. This page summarizes publicly available regulatory and research information about Octreotide / Lanreotide. It is not a prescription, an endorsement, or an offer to dispense, and regulatory status can change. Clinicians should verify current status before prescribing or compounding.